ArriVent BioPharma, Inc. Common Stock
NASDAQ Global MarketTotal Valuation
ArriVent BioPharma, Inc. Common Stock carries a market capitalization of 1.39B, placing it among publicly traded companies globally. Its enterprise value stands at 612.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.39B |
| Enterprise Value | 612.12M |
Share Statistics
ArriVent BioPharma, Inc. Common Stock currently has 45.31M shares outstanding.
| Shares Outstanding | 45.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -2.09 |
| P/TBV Ratio | 2.90 |
| P/FCF Ratio | -6.98 |
| P/OCF Ratio | -6.98 |
Financial Position
ArriVent BioPharma, Inc. Common Stock maintains a current ratio of 13.95, meaning it holds 13.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.95 |
| Quick Ratio | 13.06 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -51.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
ArriVent BioPharma, Inc. Common Stock's stock has gained approximately 31.07394% over the past 52 weeks. The 50-day moving average sits at 27.59, while the 200-day moving average is 22.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | 31.07394% |
| 50-Day Moving Average | 27.59 |
| 200-Day Moving Average | 22.71 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -156.87M, while operating income came in at -156.87M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -156.87M |
| Pretax Income | -145.24M |
| Net Income | -145.24M |
| EBITDA | -156.87M |
| EBIT | -156.87M |
| Earnings Per Share (EPS) | -3.57 |
Balance Sheet
ArriVent BioPharma, Inc. Common Stock holds 326.38M in cash and equivalents against 419,000.00 in total debt, resulting in a net debt position of -62.10M. Total book value stands at -447.96M, with working capital of 323.71M providing operational flexibility.
| Cash & Cash Equivalents | 326.38M |
| Total Debt | 419,000.00 |
| Net Debt | -62.10M |
| Equity (Book Value) | -447.96M |
| Book Value Per Share | -11.02 |
| Working Capital | 323.71M |
Cash Flow
ArriVent BioPharma, Inc. Common Stock produced -134.47M in operating cash flow over the past twelve months.
| Operating Cash Flow | -134.47M |
| Capital Expenditures | N/A |
| Free Cash Flow | -134.47M |
| FCF Per Share | -3.31 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -26.78 |
| FCF Yield | -14.33 |
Scores
ArriVent BioPharma, Inc. Common Stock posts an Altman Z-Score of 20.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 20.07 |